You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsoprenaline
Accession NumberDB01064  (APRD00182)
TypeSmall Molecule
GroupsApproved
DescriptionIsopropyl analog of epinephrine; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. [PubChem]
Structure
Thumb
Synonyms
(+-)-Isoprenaline
(+-)-Isoproterenol
(±)-isoprenaline
(±)-isoproterenol
1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol
1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol
3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol
alpha-(Isopropylaminomethyl)protocatechuyl alcohol
Isoprenalina
Isoprenaline
Isoprenalinum
Isopropyl noradrenaline
Isoproterenol
N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine
N-isopropyl-β-dihydroxyphenyl-β-hydroxyethylamine
N-Isopropylnoradrenaline
N-Isopropylnorepinephrine
α-(isopropylaminomethyl)protocatechuyl alcohol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Isoproterenol HCl Inj 1:5000Liquid.2 mgIntravenousInternational Medication Systems Ltd.1977-12-311997-08-15Canada
Isoproterenol Hydrochloride Injection USPSolution0.2 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1991-12-31Not applicableCanada
Isoproterenol Hydrochloride Injection USPSolution0.2 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories LtdNot applicableNot applicableCanada
IsuprelInjection, solution.2 mg/mLIntracardiac; Intramuscular; Intravenous; SubcutaneousValeant Pharmaceuticals North America LLC2013-12-01Not applicableUs
IsuprelInjection, solution.2 mg/mLIntracardiac; Intramuscular; Intravenous; SubcutaneousGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
IsuprelInjection, solution.2 mg/mLIntracardiac; Intramuscular; Intravenous; SubcutaneousHospira, Inc.2012-06-182016-10-13Us
IsuprelInjection, solution.2 mg/mLIntracardiac; Intramuscular; Intravenous; SubcutaneousCardinal Health2012-06-18Not applicableUs
IsuprelInjection, solution.2 mg/mLIntracardiac; Intramuscular; Intravenous; SubcutaneousHospira, Inc.2013-03-21Not applicableUs
IsuprelInjection, solution.2 mg/mLIntracardiac; Intramuscular; Intravenous; SubcutaneousCardinal Health2012-06-18Not applicableUs
IsuprelInjection, solution.2 mg/mLIntracardiac; Intramuscular; Intravenous; SubcutaneousMarathon Pharmaceuticals, LLC2013-12-012016-08-31Us
Isuprel Inj 0.2mg/mlLiquid.2 mgIntramuscular; Intravenous; SubcutaneousSterling Winthrop Inc.1992-12-311996-09-10Canada
Isuprel Liq 0.2mg/mlLiquid.2 mgIntracardiac; Intramuscular; Intravenous; SubcutaneousSanofi Canada, Inc.1956-12-312001-08-10Canada
Isuprel Liq 0.5%Liquid.5 %Respiratory (inhalation)Sanofi Canada, Inc.1954-12-311999-07-15Canada
Isuprel Liq Inh 0.5%Liquid.5 %Respiratory (inhalation)Sterling Winthrop Inc.1992-12-311996-09-10Canada
Isuprel Mistometer 125mcg/aemAerosol, metered125 mcgRespiratory (inhalation)Sterling Winthrop Inc.1992-12-311996-09-10Canada
Isuprel Mistometer Aem 0.25%Aerosol, metered0.25 %Respiratory (inhalation)Sanofi Canada, Inc.1958-12-311998-10-24Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Medihaler-IsoRiker
Proternol LKowa Souyaku
SaventrinePharmax
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Isoprenaline Hydrochloride
Thumb
  • InChI Key: IROWCYIEJAOFOW-UHFFFAOYNA-N
  • Monoisotopic Mass: 247.097521154
  • Average Mass: 247.719
DBSALT000429
Isoproterenol sulfate
ThumbNot applicableDBSALT001403
Categories
UNIIL628TT009W
CAS number7683-59-2
WeightAverage: 211.2576
Monoisotopic: 211.120843415
Chemical FormulaC11H17NO3
InChI KeyJWZZKOKVBUJMES-UHFFFAOYSA-N
InChI
InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3
IUPAC Name
4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol
SMILES
CC(C)NCC(O)C1=CC(O)=C(O)C=C1
Pharmacology
IndicationFor the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis
Structured Indications
PharmacodynamicsIsoproterenol is a relatively selective beta2-adrenergic bronchodilator. Isoproterenol is indicated for the relief of bronchospasm associated with chronic obstructive pulmonary disease. The pharmacologic effects of beta adrenergic agonist drugs, including Isoproterenol, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Mechanism of actionThe pharmacologic effects of isoproterenol are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
agonist
HumanP08588 details
Beta-2 adrenergic receptorProteinyes
agonist
HumanP07550 details
Beta-3 adrenergic receptorProteinyes
agonist
HumanP13945 details
Mitogen-activated protein kinase 1Proteinunknown
inducer
HumanP28482 details
Phosphatidylinositol 3-kinase regulatory subunit alphaProteinunknown
agonist
HumanP27986 details
Phosphatidylinositol 3-kinase regulatory subunit betaProteinunknown
agonist
HumanO00459 details
Phosphatidylinositol 3-kinase regulatory subunit gammaProteinunknown
agonist
HumanQ92569 details
CAMP phosphodiesteraseProteinunknown
activator
Trypanosoma cruziQ4ZHU6 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationExcretion following inhalation administration is primarily renal and the major metabolite is the sulfate conjugate of isoproterenol.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Isoprenaline Action PathwayDrug actionSMP00663
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Isoprenaline.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Isoprenaline.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Isoprenaline.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Isoprenaline.Experimental
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Isoprenaline.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Isoprenaline.Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Isoprenaline.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Isoprenaline.Approved, Illicit
AtenololAtenolol may decrease the bronchodilatory activities of Isoprenaline.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Isoprenaline.Approved
AtosibanThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Atosiban.Approved
BendroflumethiazideIsoprenaline may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Isoprenaline.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Isoprenaline.Approved, Illicit
Benzylpenicilloyl PolylysineIsoprenaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Isoprenaline can be decreased when used in combination with Betahistine.Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Isoprenaline.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Isoprenaline.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Isoprenaline.Approved
BromocriptineBromocriptine may increase the hypertensive activities of Isoprenaline.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Bucindolol.Investigational
BumetanideIsoprenaline may increase the hypokalemic activities of Bumetanide.Approved
BupranololBupranolol may decrease the bronchodilatory activities of Isoprenaline.Approved
CabergolineCabergoline may increase the hypertensive activities of Isoprenaline.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Isoprenaline.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Isoprenaline.Approved
CarvedilolCarvedilol may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
CeliprololCeliprolol may decrease the bronchodilatory activities of Isoprenaline.Approved, Investigational
ChlorothiazideIsoprenaline may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Chlorphentermine.Illicit, Withdrawn
ChlorthalidoneIsoprenaline may increase the hypokalemic activities of Chlorthalidone.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Clenbuterol.Approved, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isoprenaline.Approved, Vet Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Isoprenaline.Approved
DesfluraneDesflurane may increase the arrhythmogenic activities of Isoprenaline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Isoprenaline.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Isoprenaline.Approved
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Isoprenaline.Approved
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Isoprenaline.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Isoprenaline.Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Isoprenaline.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Isoprenaline.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Isoprenaline.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Doxofylline.Approved
DronabinolDronabinol may increase the tachycardic activities of Isoprenaline.Approved, Illicit
DuloxetineDuloxetine may increase the tachycardic activities of Isoprenaline.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Isoprenaline.Approved
EnfluraneEnflurane may increase the arrhythmogenic activities of Isoprenaline.Approved, Vet Approved
EphedrineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Ephedrine.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Isoprenaline.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Isoprenaline.Approved
ErgonovineErgonovine may increase the hypertensive activities of Isoprenaline.Approved
ErgotamineErgotamine may increase the hypertensive activities of Isoprenaline.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Isoprenaline.Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Etacrynic acidIsoprenaline may increase the hypokalemic activities of Etacrynic acid.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Etilefrine.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Fenoterol.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Isoprenaline.Approved, Vet Approved
FurosemideIsoprenaline may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
HalothaneHalothane may increase the arrhythmogenic activities of Isoprenaline.Approved, Vet Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Isoprenaline.Approved
HydrochlorothiazideIsoprenaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideIsoprenaline may increase the hypokalemic activities of Hydroflumethiazide.Approved
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Hydroxyamphetamine hydrobromide.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isoprenaline.Approved
IndapamideIsoprenaline may increase the hypokalemic activities of Indapamide.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Isoprenaline.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Isoprenaline.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Isoprenaline.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Isoprenaline.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoprenaline.Approved
IsofluraneIsoflurane may increase the arrhythmogenic activities of Isoprenaline.Approved, Vet Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Isoxsuprine.Approved, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Isoprenaline.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Isoprenaline.Approved
LinezolidLinezolid may increase the hypertensive activities of Isoprenaline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Isoprenaline.Withdrawn
MephentermineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Mephentermine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Isoprenaline.Approved, Investigational
MethamphetamineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Methamphetamine.Approved, Illicit
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Isoprenaline.Approved
MethoxyfluraneMethoxyflurane may increase the arrhythmogenic activities of Isoprenaline.Approved, Vet Approved
MethyclothiazideIsoprenaline may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Isoprenaline.Investigational
MetolazoneIsoprenaline may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Isoprenaline.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Isoprenaline.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Isoprenaline.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Isoprenaline.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Isoprenaline.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Isoprenaline.Approved
NabiloneNabilone may increase the tachycardic activities of Isoprenaline.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Isoprenaline.Approved
NebivololNebivolol may decrease the bronchodilatory activities of Isoprenaline.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Isoprenaline.Withdrawn
Nitrous oxideNitrous oxide may increase the arrhythmogenic activities of Isoprenaline.Approved, Vet Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Isoprenaline.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Isoprenaline.Approved
NylidrinThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Isoprenaline.Withdrawn
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Isoprenaline.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Isoprenaline.Approved
OxprenololOxprenolol may decrease the bronchodilatory activities of Isoprenaline.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Isoprenaline.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Isoprenaline.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Isoprenaline.Approved, Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isoprenaline.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Isoprenaline.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Isoprenaline.Approved, Illicit
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Isoprenaline.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Isoprenaline.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Isoprenaline.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Isoprenaline.Approved, Vet Approved, Withdrawn
PindololPindolol may decrease the bronchodilatory activities of Isoprenaline.Approved
PiretanideIsoprenaline may increase the hypokalemic activities of Piretanide.Experimental
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Isoprenaline.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Isoprenaline.Withdrawn
PolythiazideIsoprenaline may increase the hypokalemic activities of Polythiazide.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Isoprenaline.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Procaterol.Approved
PropranololPropranolol may decrease the bronchodilatory activities of Isoprenaline.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isoprenaline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Pseudoephedrine.Approved
QuinethazoneIsoprenaline may increase the hypokalemic activities of Quinethazone.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Racepinephrine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isoprenaline.Approved
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Isoprenaline.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Isoprenaline.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Isoprenaline.Approved, Investigational, Vet Approved
SevofluraneSevoflurane may increase the arrhythmogenic activities of Isoprenaline.Approved, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Isoprenaline.Approved
SotalolSotalol may decrease the bronchodilatory activities of Isoprenaline.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Isoprenaline.Approved
SynephrineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Isoprenaline.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Isoprenaline.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Isoprenaline.Approved
TetryzolineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Tetryzoline.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Isoprenaline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Isoprenaline.Approved
TimololTimolol may decrease the bronchodilatory activities of Isoprenaline.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Isoprenaline.Approved
TorasemideIsoprenaline may increase the hypokalemic activities of Torasemide.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Isoprenaline.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoprenaline.Approved
TrichlormethiazideIsoprenaline may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Isoprenaline.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Isoprenaline.Approved
TyramineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Tyramine.Investigational, Nutraceutical
VenlafaxineVenlafaxine may increase the tachycardic activities of Isoprenaline.Approved
Food InteractionsNot Available
References
Synthesis Reference

U.S. Patent 2,308,232.
U.S. Patent 2,715,141.

General ReferencesNot Available
External Links
ATC CodesR03AK02R03CB51R03CB01R03AB02C01CA02
AHFS Codes
  • 12:12.08.04
  • 52:92.00
  • 84:04.12
  • 84:04.92
PDB EntriesNot Available
FDA labelDownload (314 KB)
MSDSDownload (73.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9936
Blood Brain Barrier-0.9705
Caco-2 permeable-0.6775
P-glycoprotein substrateSubstrate0.5776
P-glycoprotein inhibitor INon-inhibitor0.9039
P-glycoprotein inhibitor IINon-inhibitor0.9709
Renal organic cation transporterNon-inhibitor0.8983
CYP450 2C9 substrateNon-substrate0.7778
CYP450 2D6 substrateNon-substrate0.6679
CYP450 3A4 substrateNon-substrate0.6939
CYP450 1A2 substrateInhibitor0.6221
CYP450 2C9 inhibitorNon-inhibitor0.9558
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9484
CYP450 3A4 inhibitorNon-inhibitor0.9556
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9318
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable0.8925
Rat acute toxicity2.7434 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9576
hERG inhibition (predictor II)Non-inhibitor0.8045
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
LiquidIntravenous.2 mg
SolutionIntramuscular; Intravenous; Subcutaneous0.2 mg
Injection, solutionIntracardiac; Intramuscular; Intravenous; Subcutaneous.2 mg/mL
LiquidIntramuscular; Intravenous; Subcutaneous.2 mg
LiquidIntracardiac; Intramuscular; Intravenous; Subcutaneous.2 mg
LiquidRespiratory (inhalation).5 %
Aerosol, meteredRespiratory (inhalation)125 mcg
Aerosol, meteredRespiratory (inhalation)0.25 %
Prices
Unit descriptionCostUnit
Isuprel 0.2 mg/ml ampul17.63USD ml
Isoproterenol sulfate cryst2.86USD g
Isoproterenol 0.2 mg/ml amp0.73USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point180U.S. Patent 2,308,232. U.S. Patent 2,715,141.
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.86 mg/mLALOGPS
logP-0.27ALOGPS
logP0.24ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)9.81ChemAxon
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity58.4 m3·mol-1ChemAxon
Polarizability23.04 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as catecholamines and derivatives. These are compounds containing 4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] or a derivative thereof formed by substitution.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenols and derivatives
Direct ParentCatecholamines and derivatives
Alternative Parents
Substituents
  • Catecholamine
  • Aralkylamine
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Sato M, Gong H, Terracciano CM, Ranu H, Harding SE: Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger. J Mol Cell Cardiol. 2004 Jan;36(1):43-8. [PubMed:14734046 ]
  2. Jurgens CW, Rau KE, Knudson CA, King JD, Carr PA, Porter JE, Doze VA: Beta1 adrenergic receptor-mediated enhancement of hippocampal CA3 network activity. J Pharmacol Exp Ther. 2005 Aug;314(2):552-60. Epub 2005 May 20. [PubMed:15908512 ]
  3. Kobayashi H, Narita Y, Nishida M, Kurose H: Beta-arrestin2 enhances beta2-adrenergic receptor-mediated nuclear translocation of ERK. Cell Signal. 2005 Oct;17(10):1248-53. Epub 2005 Feb 12. [PubMed:16038799 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4. [PubMed:10722 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Abraham G, Kottke C, Dhein S, Ungemach FR: Pharmacological and biochemical characterization of the beta-adrenergic signal transduction pathway in different segments of the respiratory tract. Biochem Pharmacol. 2003 Sep 15;66(6):1067-81. [PubMed:12963495 ]
  2. Jones SM, Hiller FC, Jacobi SE, Foreman SK, Pittman LM, Cornett LE: Enhanced beta2-adrenergic receptor (beta2AR) signaling by adeno-associated viral (AAV)-mediated gene transfer. BMC Pharmacol. 2003 Dec 4;3:15. [PubMed:14656380 ]
  3. Teixeira CE, Baracat JS, Zanesco A, Antunes E, De Nucci G: Atypical beta-adrenoceptor subtypes mediate relaxations of rabbit corpus cavernosum. J Pharmacol Exp Ther. 2004 May;309(2):587-93. Epub 2004 Jan 29. [PubMed:14752060 ]
  4. Odley A, Hahn HS, Lynch RA, Marreez Y, Osinska H, Robbins J, Dorn GW 2nd: Regulation of cardiac contractility by Rab4-modulated beta2-adrenergic receptor recycling. Proc Natl Acad Sci U S A. 2004 May 4;101(18):7082-7. Epub 2004 Apr 22. [PubMed:15105445 ]
  5. Uezono Y, Kaibara M, Murasaki O, Taniyama K: Involvement of G protein betagamma-subunits in diverse signaling induced by G(i/o)-coupled receptors: study using the Xenopus oocyte expression system. Am J Physiol Cell Physiol. 2004 Oct;287(4):C885-94. Epub 2004 May 19. [PubMed:15151902 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4. [PubMed:10722 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Molecular Weight:
43518.615 Da
References
  1. Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4. [PubMed:10722 ]
  2. Schiffelers SL, Blaak EE, Saris WH, van Baak MA: In vivo beta3-adrenergic stimulation of human thermogenesis and lipid use. Clin Pharmacol Ther. 2000 May;67(5):558-66. [PubMed:10824635 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Rna polymerase ii carboxy-terminal domain kinase activity
Specific Function:
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell...
Gene Name:
MAPK1
Uniprot ID:
P28482
Molecular Weight:
41389.265 Da
References
  1. Vaniotis G, Del Duca D, Trieu P, Rohlicek CV, Hebert TE, Allen BG: Nuclear beta-adrenergic receptors modulate gene expression in adult rat heart. Cell Signal. 2011 Jan;23(1):89-98. doi: 10.1016/j.cellsig.2010.08.007. Epub 2010 Aug 21. [PubMed:20732414 ]
  2. Oudit GY, Crackower MA, Eriksson U, Sarao R, Kozieradzki I, Sasaki T, Irie-Sasaki J, Gidrewicz D, Rybin VO, Wada T, Steinberg SF, Backx PH, Penninger JM: Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation. 2003 Oct 28;108(17):2147-52. Epub 2003 Sep 8. [PubMed:12963636 ]
  3. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Pineyro G: Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11406-11. Epub 2003 Sep 17. [PubMed:13679574 ]
  4. Adissu HA, Schuller HM: Antagonistic growth regulation of cell lines derived from human lung adenocarcinomas of Clara cell and aveolar type II cell lineage: Implications for chemoprevention. Int J Oncol. 2004 Jun;24(6):1467-72. [PubMed:15138589 ]
  5. Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B: Catecholamines block the antimitogenic effect of estradiol on human coronary artery smooth muscle cells. J Clin Endocrinol Metab. 2004 Aug;89(8):3922-31. [PubMed:15292328 ]
  6. Yeh CK, Ghosh PM, Dang H, Liu Q, Lin AL, Zhang BX, Katz MS: beta-Adrenergic-responsive activation of extracellular signal-regulated protein kinases in salivary cells: role of epidermal growth factor receptor and cAMP. Am J Physiol Cell Physiol. 2005 Jun;288(6):C1357-66. Epub 2005 Feb 2. [PubMed:15689414 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Transmembrane receptor protein tyrosine kinase adaptor activity
Specific Function:
Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PD...
Gene Name:
PIK3R1
Uniprot ID:
P27986
Molecular Weight:
83597.675 Da
References
  1. Slomiany BL, Slomiany A: Salivary phospholipid secretion in response to beta-adrenergic stimulation is mediated by Src kinase-dependent epidermal growth factor receptor transactivation. Biochem Biophys Res Commun. 2004 May 21;318(1):247-52. [PubMed:15110780 ]
  2. Slomiany BL, Slomiany A: Secretion of gastric mucus phospholipids in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2004 Sep;55(3):627-38. [PubMed:15381832 ]
  3. Slomiany BL, Slomiany A: Src-kinase-dependent epidermal growth factor receptor transactivation in salivary mucin secretion in response to beta-adrenergic G-protein-coupled receptor activation. Inflammopharmacology. 2004;12(3):233-45. [PubMed:15527548 ]
  4. Machida K, Inoue H, Matsumoto K, Tsuda M, Fukuyama S, Koto H, Aizawa H, Kureishi Y, Hara N, Nakanishi Y: Activation of PI3K-Akt pathway mediates antiapoptotic effects of beta-adrenergic agonist in airway eosinophils. Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L860-7. Epub 2004 Dec 23. [PubMed:15618457 ]
  5. Slomiany BL, Slomiany A: Gastric mucin secretion in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2005 Jun;56(2):247-58. [PubMed:15985706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Receptor tyrosine kinase binding
Specific Function:
Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility...
Gene Name:
PIK3R2
Uniprot ID:
O00459
Molecular Weight:
81544.505 Da
References
  1. Slomiany BL, Slomiany A: Salivary phospholipid secretion in response to beta-adrenergic stimulation is mediated by Src kinase-dependent epidermal growth factor receptor transactivation. Biochem Biophys Res Commun. 2004 May 21;318(1):247-52. [PubMed:15110780 ]
  2. Slomiany BL, Slomiany A: Secretion of gastric mucus phospholipids in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2004 Sep;55(3):627-38. [PubMed:15381832 ]
  3. Slomiany BL, Slomiany A: Src-kinase-dependent epidermal growth factor receptor transactivation in salivary mucin secretion in response to beta-adrenergic G-protein-coupled receptor activation. Inflammopharmacology. 2004;12(3):233-45. [PubMed:15527548 ]
  4. Machida K, Inoue H, Matsumoto K, Tsuda M, Fukuyama S, Koto H, Aizawa H, Kureishi Y, Hara N, Nakanishi Y: Activation of PI3K-Akt pathway mediates antiapoptotic effects of beta-adrenergic agonist in airway eosinophils. Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L860-7. Epub 2004 Dec 23. [PubMed:15618457 ]
  5. Slomiany BL, Slomiany A: Gastric mucin secretion in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2005 Jun;56(2):247-58. [PubMed:15985706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
1-phosphatidylinositol-3-kinase regulator activity
Specific Function:
Binds to activated (phosphorylated) protein-tyrosine kinases through its SH2 domain and regulates their kinase activity. During insulin stimulation, it also binds to IRS-1.
Gene Name:
PIK3R3
Uniprot ID:
Q92569
Molecular Weight:
54448.0 Da
References
  1. Slomiany BL, Slomiany A: Salivary phospholipid secretion in response to beta-adrenergic stimulation is mediated by Src kinase-dependent epidermal growth factor receptor transactivation. Biochem Biophys Res Commun. 2004 May 21;318(1):247-52. [PubMed:15110780 ]
  2. Slomiany BL, Slomiany A: Secretion of gastric mucus phospholipids in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2004 Sep;55(3):627-38. [PubMed:15381832 ]
  3. Slomiany BL, Slomiany A: Src-kinase-dependent epidermal growth factor receptor transactivation in salivary mucin secretion in response to beta-adrenergic G-protein-coupled receptor activation. Inflammopharmacology. 2004;12(3):233-45. [PubMed:15527548 ]
  4. Machida K, Inoue H, Matsumoto K, Tsuda M, Fukuyama S, Koto H, Aizawa H, Kureishi Y, Hara N, Nakanishi Y: Activation of PI3K-Akt pathway mediates antiapoptotic effects of beta-adrenergic agonist in airway eosinophils. Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L860-7. Epub 2004 Dec 23. [PubMed:15618457 ]
  5. Slomiany BL, Slomiany A: Gastric mucin secretion in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2005 Jun;56(2):247-58. [PubMed:15985706 ]
Kind
Protein
Organism
Trypanosoma cruzi
Pharmacological action
unknown
Actions
activator
General Function:
Metal ion binding
Specific Function:
Not Available
Gene Name:
PDE4
Uniprot ID:
Q4ZHU6
Molecular Weight:
103168.655 Da
References
  1. Degerman E, Smith CJ, Tornqvist H, Vasta V, Belfrage P, Manganiello VC: Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. Proc Natl Acad Sci U S A. 1990 Jan;87(2):533-7. [PubMed:2153956 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23